Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TBPH

Theravance Biopharma Inc

Mar 04 • 04:00PM ET

13.66

-0.30 -2.11 %

Healthcare • Biotechnology • USA • NASD

Mar 03, 1:25 PMTheravance Biopharma ends ampreloxetine program, to cut about 50% of workforce and wind down R&D after failed Phase 3 CYPRESS trial

Peers: VRTX REGN GILD BMRN INCY IONS NBIX ALNY MDGL SRPT

| Held by: VTI IWM VXF IBB CALF IWO VTWO JSML JSMD SCHA

Scroll to Statements

Index	RUT	P/E	24.29	EPS (ttm)	0.56	Insider Own	6.62%	Shs Outstand	50.67M	Perf Week	-28.31%
Market Cap	692.44M	Forward P/E	8.29	EPS next Y	1.65	Insider Trans	-0.92%	Shs Float	47.32M	Perf Month	-31.09%
Enterprise Value	407.35M	PEG	-	EPS next Q	1.09	Inst Own	98.99%	Short Float	9.56%	Perf Quarter	-30.32%
Income	29.34M	P/S	8.62	EPS this Y	271.30%	Inst Trans	4.30%	Short Ratio	8.61	Perf Half Y	-1.26%
Sales	80.33M	P/B	2.98	EPS next Y	-16.32%	ROA	7.61%	Short Interest	4.52M	Perf YTD	-26.96%
Book/sh	4.59	P/C	2.10	EPS next 5Y	-	ROE	14.03%	52W High	21.03 -35.02%	Perf Year	50.16%
Cash/sh	6.51	P/FCF	2.84	EPS past 3/5Y	26.18% 22.95%	ROIC	11.02%	52W Low	7.90 72.97%	Perf 3Y	35.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.19% -2.59%	Gross Margin	93.15%	Volatility	7.32% 5.27%	Perf 5Y	-27.16%
Dividend TTM	-	EV/Sales	5.07	EPS Y/Y TTM	156.96%	Oper. Margin	-43.72%	ATR (14)	1.21	Perf 10Y	-23.53%
Dividend Ex-Date	-	Quick Ratio	9.48	Sales Y/Y TTM	27.12%	Profit Margin	36.53%	RSI (14)	22.43	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	9.48	EPS Q/Q	126.88%	SMA20	-27.11%	Beta	0.15	Target Price	21.00
Payout	-	Debt/Eq	0.19	Sales Q/Q	18.51%	SMA50	-28.52%	Rel Volume	2.71	Prev Close	13.96
Employees	97	LT Debt/Eq	0.14	Earnings	Nov 10 AMC	SMA200	-8.46%	Avg Volume	525.08K	Price	13.66
IPO	May 16, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	154.73% 0.15%	Trades		Volume	1,424,660	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	B. Riley Securities	Buy → Neutral	$14
Dec-03-25	Initiated	Oppenheimer	Outperform	$27
Sep-12-25	Initiated	B. Riley Securities	Buy	$28
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform	$15 → $10
Apr-12-24	Initiated	BTIG Research	Buy	$21
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45
Aug-17-17	Initiated	Evercore ISI	Outperform	$45

Show Previous Ratings

Today 10:34AM	TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study (Zacks)
07:32AM	Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure (Clinical Trials Arena)
Mar-03-26 04:15PM	The Excruciating Failure That Could Prompt Theravance, Down 26%, To Sell Itself (Investor's Business Daily) -26.33%
01:19PM	Theravance Biopharma Plummets As Phase 3 Study Falls Short (Benzinga)
12:18PM	The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself (Investor's Business Daily)
11:05AM	Loading…
11:05AM	Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review (Proactive)
08:30AM	Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions (PR Newswire)
Feb-24-26 08:02AM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
Jan-28-26 01:15PM	Is the Options Market Predicting a Spike in Theravance Biopharma Stock? (Zacks)
Jan-23-26 09:50AM	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 09:45AM	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
Jan-06-26 09:50AM	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-24-25 09:45AM	Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock (Zacks)
Dec-22-25 09:55AM	Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade (Zacks)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
12:00PM	Loading…
Dec-08-25 12:00PM	Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-05-25 09:55AM	Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? (Zacks)
09:45AM	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
Nov-20-25 11:00AM	Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 (PR Newswire)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-19-25 09:45AM	Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
06:00AM	Theravance Biopharma to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-11-25 02:14PM	Here's Why Shares in Theravance Biopharma Exploded Today (Motley Fool) +22.68%
10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)
12:04AM	Theravance Biopharma Inc (TBPH) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-10-25 05:20PM	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Theravance Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-25 09:15AM	VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
02:05PM	Loading…
Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Oct-29-25 06:00AM	Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System (PR Newswire)
Oct-27-25 06:00AM	Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire)
Oct-16-25 08:05AM	Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy (Business Wire)
Oct-14-25 06:00AM	Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting (PR Newswire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 06:00AM	Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 06:00AM	Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy (PR Newswire)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:14AM	Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... (GuruFocus.com)
Aug-12-25 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Theravance Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:29AM	Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
Jul-28-25 06:00AM	Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-23-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 08:59AM	Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma (Insider Monkey)
Jun-27-25 07:36AM	Viatris gains China approval for Yupelri to treat COPD (Pharmaceutical Technology)
Jun-26-25 06:00AM	Theravance Biopharma Announces Approval of YUPELRI (revefenacin) by China's NMPA (PR Newswire)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
Jun-02-25 06:00AM	Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million (PR Newswire) +21.72%
May-13-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.29%
12:00PM	Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress (PR Newswire)
03:47AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-08-25 06:05PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-07-25 10:52AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-06-25 05:30PM	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
Apr-28-25 06:00AM	Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress (PR Newswire)
Apr-24-25 06:00AM	Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
Apr-07-25 03:55PM	Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting (PR Newswire)
Mar-31-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-28-25 11:30AM	Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? (Zacks)
Mar-27-25 06:00AM	Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology (PR Newswire)
Feb-27-25 02:26AM	Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-26-25 05:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-25-25 10:55AM	Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result (GuruFocus.com)
Feb-20-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-12-25 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (PR Newswire)
Feb-05-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-27-25 03:57AM	Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) -7.64%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-19-24 08:00AM	Government Contractor KBR, Recently Hit by DOGE Fears, Draws Activist Investor (The Wall Street Journal)
Dec-17-24 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference (PR Newswire)
Dec-12-24 11:30AM	Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-20-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Nov-13-24 02:22AM	Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.64%
Nov-12-24 06:05PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value (PR Newswire)
Nov-11-24 07:16AM	What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings (GuruFocus.com)
Oct-24-24 06:00AM	Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 (PR Newswire)
Oct-18-24 09:00AM	Theravance Announces Publication of YUPELRI (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease (PR Newswire)
Sep-10-24 11:01AM	Seth Klarman's Complete Exit from Theravance Biopharma Inc (GuruFocus.com)
Sep-04-24 11:30AM	Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-27-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-14-24 05:03PM	Seth Klarman's Strategic Reduction in Theravance Biopharma Inc (GuruFocus.com)
Aug-06-24 10:56AM	Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -18.35%
Aug-05-24 06:00PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jul-25-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-22-24 06:00AM	Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 (PR Newswire) +7.00%
Jun-26-24 11:28AM	Here's Why You May Invest in Theravance (TBPH) Stock Now (Zacks)
Jun-21-24 09:55AM	Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know (Zacks)
Jun-12-24 11:30AM	Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Dec 03 '25	Sale	18.75	31,067	582,501	277,695	Dec 05 06:02 PM
RHONDA FARNUM	Officer	Dec 03 '25	Proposed Sale	18.75	31,067	582,500		Dec 03 04:19 PM
ERAN BROSHY	Director	Nov 26 '25	Proposed Sale	20.00	29,501	590,020		Nov 26 04:02 PM
ERAN BROSHY	Director	Nov 11 '25	Proposed Sale	17.98	45,000	809,250		Nov 12 09:02 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 14 '25	Sale	11.39	10,000	113,870	326,918	Jul 16 06:01 PM
RHONDA FARNUM	Officer	Jul 14 '25	Proposed Sale	11.39	10,000	113,869		Jul 14 04:03 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 02 '25	Sale	11.00	24,000	264,000	336,918	Jun 04 06:04 PM
RHONDA FARNUM	Officer	Jun 02 '25	Proposed Sale	11.00	24,000	264,000		Jun 02 04:25 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Apr 21 '25	Sale	9.00	4,000	36,000	370,038	Apr 23 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TBPH

Theravance Biopharma Inc

Upgrade your FINVIZ experience